MUTATIONAL ACTIVATION OF RAS AND GSP ONCOGENES IN DIFFERENTIATED THYROID-CANCER AND THEIR BIOLOGICAL IMPLICATIONS

被引:95
作者
GORETZKI, PE
LYONS, J
STACYPHIPPS, S
ROSENAU, W
DEMEURE, M
CLARK, OH
MCCORMICK, F
ROHER, HD
BOURNE, HR
机构
[1] UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA
[2] UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA
[3] UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA
[4] CETUS CORP, DEPT HUMAN GENET, EMERYVILLE, CA 94608 USA
[5] CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA
关键词
D O I
10.1007/BF02067325
中图分类号
R61 [外科手术学];
学科分类号
摘要
Activating mutations of ras-genes (Kirsten-ras, Harvey-ras, N-ras) and genes encoding for the alpha subunit of G-proteins (Gs, Gi2, Gi3, Go, Gz) were assessed in 32 differentiated thyroid cancer (DTC) tissues from German (n = 22) and American (n = 10) patients. Gs-protein (GSP) and/or ras mutations were found in 69% of all tissues with a heterogeneous distribution pattern. An increased prevalence could be demonstrated in metastatic (8 of 9 mutation positive) when compared to localized disease (13 of 23 mutation positive) (p < 0.001) and in patients > 50 years of age (16 of 18 mutation positive), when compared to younger patients (6 of 14 mutation positive) (p < 0.001). No activating mutations were found on H-ras and K-ras genes nor on genes encoding for the alpha-subunits of Gi2, Gi3, Go, and Gz. Differentiated thyroid cancer tissue from German patients revealed a higher prevalence for GSP mutations (73%) than did DTC from American patients (20%) (p < 0.001). We demonstrated a high frequency of ras and GSP mutations in DTC and suggest that these mutations may contribute to our basic understanding of this disease and might initiate a new search for more rational and individualized therapeutic approaches in patients with DTC.
引用
收藏
页码:576 / 582
页数:7
相关论文
共 46 条
[1]   MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].
ALMOGUERA, C ;
SHIBATA, D ;
FORRESTER, K ;
MARTIN, J ;
ARNHEIM, N ;
PERUCHO, M .
CELL, 1988, 53 (04) :549-554
[2]   MULTIFACTORIAL STUDY OF PROGNOSTIC FACTORS IN DIFFERENTIATED THYROID-CARCINOMA AND A REEVALUATION OF THE IMPORTANCE OF AGE [J].
BACOURT, F ;
ASSELAIN, B ;
SAVOIE, JC ;
DHUBERT, E ;
MASSIN, JP ;
DOUCET, G ;
LEGER, A ;
GARNIER, H .
BRITISH JOURNAL OF SURGERY, 1986, 73 (04) :274-277
[3]   INCREASED AGGRESSIVENESS OF THYROID-CANCER IN PATIENTS WITH GRAVES-DISEASE [J].
BELFIORE, A ;
GAROFALO, MR ;
GIUFFRIDA, D ;
RUNELLO, F ;
FILETTI, S ;
FIUMARA, A ;
IPPOLITO, O ;
VIGNERI, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :830-835
[4]  
BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675
[5]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[6]  
BOS JL, 1989, CANCER RES, V49, P4682
[7]   THE GTPASE SUPERFAMILY - A CONSERVED SWITCH FOR DIVERSE CELL FUNCTIONS [J].
BOURNE, HR ;
SANDERS, DA ;
MCCORMICK, F .
NATURE, 1990, 348 (6297) :125-132
[8]  
Clark O H, 1981, World J Surg, V5, P39
[9]   CHARACTERIZATION OF THE THYROTROPIN RECEPTOR-ADENYLATE CYCLASE SYSTEM IN NEOPLASTIC HUMAN THYROID-TISSUE [J].
CLARK, OH ;
GEREND, PL ;
GORETZKI, P ;
NISSENSON, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (01) :140-147
[10]   INDUCTION OF THE C-FOS ONCOGENE BY THYROTROPIC HORMONE IN RAT-THYROID CELLS IN CULTURE [J].
COLLETTA, G ;
CIRAFICI, AM ;
VECCHIO, G .
SCIENCE, 1986, 233 (4762) :458-460